Table 1. Baseline characteristics and design features of included trials.
| Study | N of pts* | F, % | Age, y | Inclusion criteria | Prior stroke/TIA | Experimental group | Control group | Duration of Clop+ASA | Follow-up | ||||
| Exp/Ctrl | N (%) | Duration | Lost | ||||||||||
| CARESS 2005[12] | 51/56 | 31/30 | 66/63 | Stroke/TIA(≤3 m) and carotid stenosis | 107 (100) | Clop 300 →75 mg +ASA 75 mg | ASA 75 mg | 7d | 7d | None | |||
| CLAIR 2010[16] | 46/52 | 22/23 | 59/56 | Stroke/TIA(≤7d) and intracranial stenosis | 98 (100) | Clop 300 →75 mg +ASA 75∼160 mg | ASA 75∼160 mg | 7d | 7d | 1% | |||
| COMMIT 2005[4] | 22961/22891 | 28/28 | 61/61 | Acute MI with ST changes(≤24 hrs) | NR | Clop 75 mg+ASA 162 mg | ASA 162 mg | 14.9d | 15d (∼28d) | <1% | |||
| CHANCE 2013[17] | 2584/2586 | 33/35 | 63/62 | Acute minor stroke or TIA (≤24 hrs) | 5170 (100) | Clop 300→75 mg ×90d +ASA 75 mg ×21d | ASA 75 mg×90d | 21d | 90d | 0.7% | |||
| CLARITY 2005[5] | 1752/1739 | 20/19 | 58/57 | MI with ST elevation(≤12 hrs) | NR | Clop 300→75 mg +ASA 150∼325 →75∼162 mg | ASA 150∼325 →75∼162 mg | Median of 4 doses | 30d | NR | |||
| Sun JC, 2010[28] | 49/50 | 6/14 | 66/65 | Post CABG | 5 (5.0) | Clop 300→75 mg +ASA 325→81 mg | ASA 325→81 mg | 30d | 30d | None | |||
| FASTER 2007[2] | 198/194 | 43/52 | 68/68 | TIA or minor stroke(≤24 hrs) | 392 (100) | Clop 300→75 mg +ASA 81 mg | ASA 81 mg | 90d | 90d | 1.8% | |||
| Ussia GP 2011[11] | 40/39 | 50/59 | 80/81 | Transcatheter aortic valve implantation | 10 (12.7) | Clop 300 →75 mg×3 m +ASA 100 mg | ASA 100 mg | 3 m | 6 m | None | |||
| CURE 2001[6] | 6259/6303 | 39/38 | 64/64 | ACS without ST elevation(≤24 hrs) | 506 (4.0) | Clop 300→75 mg +ASA 75∼325 mg | ASA 75∼325 mg | 9 m | 3∼12 m | <1% | |||
| CASCADE 2010[13] | 56/57 | 9/12 | 65/68 | CABG | NR | Clop 75 mg+ASA 162 mg | ASA 162 mg | 1y | 1y | None | |||
| CASPAR 2010[14] | 425/426 | 25/24 | 67/66 | Vascular bypass grafting for PAD | NR | Clop 75 mg +ASA 75∼100 mg | ASA 75∼100 mg | 351d | 1y (6–24 m) | 2.2% | |||
| REAL-LATE/ZEST-LATE 2010[18] | 1357/1344 | 30/31 | 62/62 | Stents used >12 m | 102 (3.8) | Clop 75 mg+ASA 100∼200 mg | ASA 100∼200 mg | 12.8 m | 19.2 m | <1% | |||
| CHARISMA 2006[3] | 7802/7801 | 30/30 | 64/64 | Multiple athero- thrombotic risk factors, CAD, CVD or PAD | 5701 (36.5) 4320 (27.7) ¶ | Clop 75 mg +ASA 75∼162 mg | ASA 75∼162 mg | 28 m | 28 m | <0.5% | |||
| SPS3 2012[1] | 1517/1503 | 38/36 | 63/63 | Symptomatic lacunar stroke(≤180d) | 3020 (100) | Clop 75 mg+ASA 325 mg | ASA 325 mg | 3.5y | 3.5y | 2% | |||
| ACTIVE-A 2009[7] | 3772/3782 | 41/42 | 71/71 | AF, ≥1 risk factor for stroke§ | 992 (13.1) | Clop 75 mg+ASA 75∼100 mg | ASA 75∼100 mg | 3.6y | 3.6y | <1% | |||
ACS: acute coronary syndrome; AF: atrial fibrillation; ASA: aspirin; CABG: coronary arterial bypass graft; CAD: coronary arterial disease; CVD: cerebrovascular disease; Clop: clopidogrel; Exp/Ctrl: data of the corresponding items in experimental group and control group, separately; F: female; MI: myocardial infarction; NR: not reported. TIA: transient ischemic attack. PAD: peripheral arterial disease.
*Number of patients.
Documented cerebrovascular diseases during previous 5 years.
Risk factors for stroke: an age of 75 years or more; systemic hypertension during treatment; previous stroke, transient ischemic attack, or non–central nervous system systemic embolism; a left ventricular ejection fraction of less than 45%; peripheral vascular disease; or an age of 55 to 74 years and diabetes mellitus or coronary artery disease.